Furthermore, in a small retrospective study, brain metastases were associated with the worst local response rates compared to other sites including lung, liver, adrenal gland, pancreas and lymph node in advanced RCC patients treated with single agent anti-PD-1 (96). This evidence concerns the gene PDCD1 and renal cell carcinoma.